Unlike other MMR components, germline heterozygous MSH3 mutations are not associated with increased risk of cancer, most likely because MSH2/MSH6 can also initiate repair at replication errors (Edelmann et al., 2000; Jiricny, 2006; Haugen et al., 2008). Here, MSH6 is linked to cancer.